The unusual suspects: a surprise regarding reactions to omalizumab.
Lieberman
Phil
P
Division of Allergy and Immunology, University of Tennessee, Memphis, Tennessee, USA. aac@allergymemphis.com
D000707:Anaphylaxis / Q000139:chemically induced*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D004342:Drug Hypersensitivity / Q000209:etiology*; D006801:Humans; D000069444:Omalizumab; D011136:Polysorbates / Q000009:adverse effects*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011136:Polysorbates; D000069444:Omalizumab